ALPHA1-ANTITRYPSIN DEFICIENCY
Clinical trials for ALPHA1-ANTITRYPSIN DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new ALPHA1-ANTITRYPSIN DEFICIENCY trials appear
Sign up with your email to follow new studies for ALPHA1-ANTITRYPSIN DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to halt liver damage in rare genetic disease
Disease control Recruiting nowThis study tests whether fazirsiran can reduce liver scarring (fibrosis) in people with Alpha-1 antitrypsin deficiency, a genetic condition that can cause serious liver disease. About 160 adults with moderate to severe liver scarring will receive either fazirsiran or a placebo fo…
Matched conditions: ALPHA1-ANTITRYPSIN DEFICIENCY
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 17, 2026 07:39 UTC
-
New drug targets liver damage in rare genetic disease
Disease control Recruiting nowThis study tests a drug called fazirsiran in people with Alpha-1 antitrypsin deficiency who already have mild liver scarring. The drug aims to reduce the buildup of a faulty protein that damages the liver. About 50 participants will receive either fazirsiran or a placebo for 2 ye…
Matched conditions: ALPHA1-ANTITRYPSIN DEFICIENCY
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
500 adults with rare genetic condition to be tracked for liver disease clues
Knowledge-focused Recruiting nowThis study follows 500 adults with alpha-1 antitrypsin deficiency (AATD) for up to 5 years to see how their liver disease changes over time without any special treatment. Researchers will collect medical history, yearly questionnaires, and tests to track liver scarring and other …
Matched conditions: ALPHA1-ANTITRYPSIN DEFICIENCY
Sponsor: Takeda • Aim: Knowledge-focused
Last updated May 17, 2026 07:35 UTC